Search is Powered by Google
Urology / Nephrology News

Study Of The Reproducibility Of A Fluorescence In Situ Hybridization Bladder Cancer Detection Assay

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 07 Aug 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

UroToday.com - In the June 2008 issue of Analytical & Quantitative Cytology & Histology, the authors assessed the reproducibility of the UroVysion fluorescence in situ hybridization (FISH) assay to detect bladder cancer in clinical urine specimens. Thirteen specimens (2 negative, 3 low-level positive [1-10% abnormal cells], 5 mid-level positive [11-75%], and 3 high-level positive [>75%]) were analyzed by 7 cytotechnologists. Each cytotechnologist rendered an overall diagnosis of positive or negative and determined the percentage of abnormal urothelial cells for all positive specimens.

The interobserver reproducibility of the assay was 100% for mid-level and high-level positive specimens - 93% for negative specimens, and 78% for low-level positive specimens. The range of percent abnormal determinations was highest for mid-level positive specimens, with mean standard deviations of 1.8%, 16.4% and 10.1% for the low-, mid-, and high-level positives, respectively. The authors conclude that there is a high level of reproducibility among the mid- and high-level positive specimens. However, the reproducibility for low-level positive specimens was poor, suggesting that such specimens should be reviewed by a second technologist to ensure an accurate diagnosis.

These findings should be considered by Urologists when using the UroVysion fluorescence in situ hybridization (FISH) assay to detect bladder cancer. For patients with low level positive findings, a repeat analysis is warranted before instituting biopsy or therapy.

Brankley SM, Adams EJ, Christensen MR, Everts CR, Lund JD, Oberg TN, Plagge AM, Zieman AH, Kipp BR, Halling KC

Anal Quant Cytol Histol. 2008 Jun;30(3):145-51

Reported by UroToday.com Contributing Editor David P. Wood, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday




Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader


Hormonal Therapy: Prostate image Hormonal Therapy: Prostate

Prostate cancer is the second leading cancer killer of men in the U.S. Among the treatment options for this disease are surgery, radiation therapy and hormonal therapy, which limits the effects of male hormones on growing cancer cells. Find out how hormonal therapy is being used to fight prostate...

Yeast Infections Introduction image Yeast Infections Introduction

When women experience the signs of a yeast infection, they often prefer to self-medicate rather than check with their doctor. But the symptoms are similar to those of more serious conditions and only your doctor can tell the difference. Tune is as our experts share important information all women...

View more videos...